Gastrointestinal Cancer Program

胃肠道癌症计划项目总结 梅奥临床癌症中心(MCCC)的胃肠癌(GI)计划继续取得进展 在基础、翻译和临床研究领域使用多学科的重大贡献 和互动式团队方法。GI计划的主要目标是使用新的观察结果， 机制洞察力和研究成果，使胃肠道癌症患者或胃肠道恶性肿瘤风险患者受益， 包括来自我们集水区的那些。这项工作是通过健壮的内部和 方案间互动侧重于4个目标：1)早期检测方法的应用；2) 识别和评估预测或预后的生物标志物，3)肿瘤微环境和 微生物组在癌症发生发展中的作用，以及4)个体化治疗策略。目标3是一个 新的和不断发展的努力建立在NCI资助的这些领域的现有调查人员基础上 研究，并与梅奥临床个体化医学中心内的微生物组计划互动 扩大现有的无菌小鼠设施和代谢组学核心实验室。GI计划由54个 成员来自17个部门。我们的GI计划在胰腺癌中开发了一种孢子赠款，主要是 贡献和互动仍在继续。GI计划还开发了一个肝胆(HB)孢子建议 该公司获得了极具竞争力的分数，预计将在2018年年中做出融资决定。作为这一比分的结果， MCCC从NCI获得了CCSG 75万美元的补充资金，旨在维护基础设施 用于肝癌研究。我们由NIH资助的研究平台和创新临床试验组合是 扩大3个MCCC站点以及与其他多机构网络的互动并从中受益； 这些相互作用正在提高应计利润。GI研究计划由以下总的直接资助提供支持 1020万美元(510万美元经过同行评审，其中69%来自NCI)。自2013年以来，计划成员做出了更多贡献 超过871份文献出版物，其中28%代表方案内出版物，31%反映 计划间协作；21%在影响因子为≥10的期刊上。这些出版物反映了 许多科学成就和发现，其中几个已经在实践中改变。正式 对初级教员的指导继续进行，并加大了向我们的调查人员提供试点拨款的努力。

GASTROINTESTINAL CANCER PROGRAM PROJECT SUMMARY The Gastrointestinal Cancer (GI) Program of the Mayo Clinic Cancer Center (MCCC) continues to make significant contributions in the areas of basic, translational, and clinical research by using a multidisciplinary and interactive team approach. The primary objective of the GI Program is to use novel observations, mechanistic insights and research outcomes to benefit patients with GI cancers or at risk for GI malignancies, including those from our catchment area. This work is accomplished through robust intra- and interprogrammatic interactions focused on 4 Aims: 1) application of early detection approaches, 2) identification and evaluation of predictive or prognostic biomarkers, 3) role of the tumor microenvironment and microbiome in cancer development and progression, and 4) individualized therapeutic strategies. Aim 3 is a new and evolving effort that builds upon an existing base of NCI-funded investigators in these fields of research, and interacts with the Microbiome Program within the Mayo Clinic Center for Individualized Medicine to expand the existing germ-free mouse facility and a metabolomics core lab. The GI Program consists of 54 members from 17 departments. Our GI Program developed a SPORE grant in Pancreatic Cancer where major contributions and interactions continue. The GI Program also developed a Hepatobiliary (HB) SPORE proposal that received a highly competitive score with a funding decision expected in mid-2018. As a result of this score, the MCCC was awarded a CCSG supplement of $750K from the NCI with an aim to maintain the infrastructure for liver cancer research. Our NIH-funded research platform and portfolio of innovative clinical trials is expanding and benefits from interactions across the 3 MCCC sites and with other multi-institutional networks; these interactions are enhancing accrual. The GI research program is supported by total direct funding of $10.2M ($5.1M peer-reviewed, with 69% from NCI). Since 2013, Program members have contributed more than 871 publications to the literature, of which 28% represent intraprogrammatic and 31% reflect interprogrammatic collaborations; 21% are in journals with an impact factor ≥10. These publications reflect numerous scientific accomplishments and discoveries, several of which have been practice changing. Formal mentoring of junior faculty continues with an increased effort to provide pilot grant funding to our investigators.